發送短信 : Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

 _    _    _    _    ______      ___      ____    
| \  / || | || | || |      \\   / _ \\   |  _ \\  
|  \/  || | || | || |  --  //  | / \ ||  | |_| || 
| .  . || | \\_/ || |  --  \\  | \_/ ||  | .  //  
|_|\/|_||  \____//  |______//   \___//   |_|\_\\  
`-`  `-`    `---`   `------`    `---`    `-` --`